An allosteric inhibitor of SHP-2
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

IACS-13909

Item No. 40654

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl-4-piperidinamine
CAS Number
2160546-07-4
Molecular Formula
C17H18Cl2N6
Formula Weight
377.3
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Sparingly Soluble: 1-10 mg/mlEthanol: Sparingly Soluble: 1-10 mg/ml
SMILES
ClC1=CC=CC(C2=NNC3=NC(N4CCC(C)(CC4)N)=CN=C32)=C1Cl
InChi Code
InChI=1S/C17H18Cl2N6/c1-17(20)5-7-25(8-6-17)12-9-21-15-14(23-24-16(15)22-12)10-3-2-4-11(18)13(10)19/h2-4,9H,5-8,20H2,1H3,(H,22,23,24)
InChi Key
AMADCPJVPLUGQO-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $171

    Add

    10 mg

    $325

    Add

    50 mg

    $598

    Add

    100 mg

    $1,023

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    IACS-13909 is an allosteric inhibitor of Src homology region 2 domain-containing phosphatase 2 (SHP-2; IC50 = 11 nM).1 It binds wild-type SHP-2 and SHP-2 containing a constitutively activating glutamate-to-lysine substitution at position 76 (SHP-2E76K; Kds = 49 and 211 nM, respectively). IACS-13909 decreases the levels of phosphorylated ERK in KYSE-520 esophageal squamous cell carcinoma cells (IC50 = 47 nM) but also inhibits human-ether-a-go-go (hERG) channels (IC50 = 180 nM in whole-cell patch-clamp assays using CHO cells). It decreases tumor volume without affecting body weight in an EGFR-overexpressing KYSE-520 mouse xenograft model when administered at a dose of 70 mg/kg per day.2 IACS-13909 (70 mg/kg per day) induces sustained reduction in tumor volume after dosing cessation in a non-small cell lung cancer (NSCLC) mouse xenograft model using H1975 cells expressing drug-resistant EGFRL858R/T790M/C797S.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Czako, B., Sun, Y., McAfoos, T., et al. Discovery of 6-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a potent and orally bioavailable SHP2 inhibitor. J. Med. CHem. 64(20), 15141-15169 (2021).

    2. Sun, Y., Meyers, B.A., Czako, B., et al. Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib. Cancer Res. 80(21), 4840-4853 (2020).